10% Owner Broadwood Partners Buys $3M in Recent Registered Direct Offering at Premium
IMDX has more than doubled off its 52-week low of $2.21 on elevated volume (2.2× avg).
Summary
A 10% owner, Broadwood Partners, purchased $3 million in Insight Molecular Diagnostics' recent registered direct offering, buying shares at a premium to the current market price.
Key Events · Ownership and Investor Activity · IMDX
-
Significant Insider Purchase
Broadwood Partners, a 10% owner, acquired 521,739 shares of common stock for a total of $2,999,999 on February 10, 2026.
-
Participation in Recent Offering
This purchase was part of the company's $26 million registered direct offering, which was announced on February 11-12, 2026.
-
Premium Pricing
The shares were acquired at a price of $5.75 per share, which is a premium compared to the current stock price of $5.58.
Analysis · IMDX · Life Sciences
Broadwood Partners, a significant 10% owner, demonstrated strong confidence in Insight Molecular Diagnostics by purchasing nearly $3 million worth of common stock in the company's recently completed $26 million registered direct offering. This substantial investment, representing 1.876% of the company's market capitalization, is particularly notable as it was executed at $5.75 per share, a premium to the current market price of $5.58. This insider buying reinforces the positive signal from the successful capital raise, suggesting that a major institutional investor sees significant value in the company's future.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMDX was trading at $5.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.9M. The 52-week trading range was $2.21 to $8.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.